uniQure N.V. (QURE) EPS Estimated At $-0.68

March 14, 2018 - By Louis Casey

 uniQure N.V. (QURE) EPS Estimated At $ 0.68

Analysts expect uniQure N.V. (NASDAQ:QURE) to report $-0.68 EPS on March, 21.They anticipate $0.42 EPS change or 161.54 % from last quarter’s $-0.26 EPS. After having $-0.40 EPS previously, uniQure N.V.’s analysts see 70.00 % EPS growth. The stock decreased 10.23% or $2.57 during the last trading session, reaching $22.54. About 473,113 shares traded or 19.61% up from the average. uniQure N.V. (NASDAQ:QURE) has declined 52.65% since March 14, 2017 and is downtrending. It has underperformed by 69.35% the S&P500.

uniQure N.V. (NASDAQ:QURE) Ratings Coverage

Among 13 analysts covering uniQure N.V. (NASDAQ:QURE), 10 have Buy rating, 0 Sell and 3 Hold. Therefore 77% are positive. uniQure N.V. had 28 analyst reports since August 7, 2015 according to SRatingsIntel. Piper Jaffray downgraded the stock to “Neutral” rating in Wednesday, November 16 report. The firm has “Buy” rating by Roth Capital given on Monday, November 30. On Friday, August 28 the stock rating was maintained by Piper Jaffray with “Overweight”. Evercore initiated uniQure N.V. (NASDAQ:QURE) on Tuesday, November 7 with “Buy” rating. WallachBeth Capital maintained the stock with “Buy” rating in Wednesday, June 15 report. The rating was maintained by Piper Jaffray on Monday, September 21 with “Buy”. The firm has “Buy” rating given on Monday, November 30 by TH Capital. On Tuesday, December 1 the stock rating was initiated by Janney Capital with “Buy”. The company was maintained on Wednesday, July 12 by Cowen & Co. Jefferies downgraded the shares of QURE in report on Tuesday, November 22 to “Hold” rating.

uniQure N.V., a biopharmaceutical company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. The company has market cap of $692.46 million. The company's principle programs include AMT-060, a gene therapy that has completed Phase I/II clinical trial for the treatment of hemophilia B; S100A1, a preclinical product candidate for the treatment of congestive heart failure; and AMT-130 for the treatment of huntington's disease. It currently has negative earnings. It also provides Glybera, a gene therapy product that has approved for the treatment of patients with lipoprotein lipase deficiency.

More recent uniQure N.V. (NASDAQ:QURE) news were published by: Streetinsider.com which released: “Form 8-K uniQure NV For: Mar 14” on March 14, 2018. Also Seekingalpha.com published the news titled: “uniQure reports FY results” on March 14, 2018. Nasdaq.com‘s news article titled: “uniQure Announces 2017 Financial Results and Recent Company Progress” with publication date: March 14, 2018 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: